Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$902.69 - $993.35 $92,977 - $102,315
-103 Reduced 13.36%
668 $642,000
Q4 2023

Feb 06, 2024

BUY
$775.18 - $881.7 $198,446 - $225,715
256 Added 49.71%
771 $677,000
Q3 2023

Nov 03, 2023

BUY
$692.45 - $844.37 $7,616 - $9,288
11 Added 2.18%
515 $423,000
Q2 2023

Aug 04, 2023

BUY
$700.03 - $830.35 $63,002 - $74,731
90 Added 21.74%
504 $362,000
Q1 2023

May 01, 2023

BUY
$680.49 - $826.97 $25,858 - $31,424
38 Added 10.11%
414 $340,000
Q4 2022

Feb 07, 2023

BUY
$705.89 - $766.39 $265,414 - $288,162
376 New
376 $271,000
Q1 2020

Apr 24, 2020

SELL
$336.18 - $494.43 $218,853 - $321,873
-651 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$274.13 - $376.51 $178,458 - $245,108
651 New
651 $245,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Lincoln National Corp Portfolio

Follow Lincoln National Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

News

Stay updated on Lincoln National Corp with notifications on news.